Yu M, Feng XY, Yao S, Wang C, Yang P. Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis. World J Clin Cases 2022; 10(26): 9524-9535 [PMID: 36159441 DOI: 10.12998/wjcc.v10.i26.9524]
Corresponding Author of This Article
Ping Yang, MD, PhD, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, No. 126 Xiantai Street, Changchun 130031, Jilin Province, China. pyang@jlu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2022; 10(26): 9524-9535 Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9524
Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis
Ming Yu, Xiao-Yu Feng, Shuai Yao, Chang Wang, Ping Yang
Ming Yu, Chang Wang, Ping Yang, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, Changchun 130031, Jilin Province, China
Xiao-Yu Feng, Department of Endocrinology, Jilin Guowen Hospital, Changchun 130021, Jilin Province, China
Shuai Yao, Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun 130031, Jilin Province, China
Author contributions: Yu M and Feng XY conceived and designed the study; Yao S and Wang C collected and analyzed data; Yu M wrote the draft of the study; Yang P was responsible for the revision of the manuscript for important intellectual content; All authors issued final approval for the version to be submitted.
Supported byNational Natural Science Foundation of China, No. 81570360.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ping Yang, MD, PhD, Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, No. 126 Xiantai Street, Changchun 130031, Jilin Province, China. pyang@jlu.edu.cn
Received: April 15, 2022 Peer-review started: April 15, 2022 First decision: June 7, 2022 Revised: June 11, 2022 Accepted: August 9, 2022 Article in press: August 9, 2022 Published online: September 16, 2022 Processing time: 140 Days and 0.3 Hours
Abstract
BACKGROUND
Sulfonylurea (SU) is a commonly used antidiabetic drugs effective for type 2 diabetes mellitus. Previous studies have reported that the SU treatment could alter the serum free fatty acid (FFA) concentration in diabetic patients; however, their exact effects remain unknown.
AIM
To assess the impact of SU on the FFA level in diabetic patients.
METHODS
A systematic literature search was conducted by consulting the PubMed, EMBASE, Cochrane Library, Reference Citation Analysis (https://www.referencecitationanalysis.com/), and Web of Science databases from January 1, 1991 to July 30, 2021. Either a fixed-effects model or random-effects model was applied to study the association between SU treatment and FFA concentration according to the heterogeneity test. Two investigators independently performed data extraction. The mean difference (MD) and corresponding 95% confidence interval (CI) were used to measure effect size. R3.5.1 software was utilized for conducting statistical analyses.
RESULTS
A total of 13 studies with 2273 individuals were selected. Results indicated that FFA concentration increased slightly after treatment with SU (MD = 0.08, 95%CI: 0.03-0.12, P < 0.01). In addition, we found that SU treatment combined with other antidiabetics could also increase the concentration of serum FFA (MD = 0.14, 95%CI: 0.01-0.28, P < 0.01). Regarding the type of SU, there was no significant difference in FFA concentration with glimepiride or glibenclamide. FFA concentration was higher at ≥ 12 wk (MD = 0.09, 95%CI: 0.04-0.13) but not at < 12 wk (MD = 0.01, 95%CI: -0.07-0.09).
CONCLUSION
SU treatment could increase the serum FFA concentration in diabetic patients. The fundamental underlying mechanism still needs further investigation.
Core Tip: The effect of sulfonylurea (SU) therapy on free fatty acid (FFA) concentration in diabetic patients has not been determined. This is the first systematic review and meta-analysis to assess the impact of SU on FFA. The present study indicated that SU therapy could increase FFA concentration in diabetic patients. Further research is required to confirm the association between FFA concentration and SU treatment.
